Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919555 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00919555 is a Phase 1 study that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 28 participants.
The verdict
NCT00919555, a Phase 1 study, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and the efficacy of Tretinoin and Pioglitazone HCL in patients with ALS who are currently on Riluzole.
Interventions
- DRUG Placebo
- DRUG Pioglitazone and Tretinoin
- DRUG Tretinoin and Pioglitazone HCL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919555
The ClinicalTrials.gov registry entry for NCT00919555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix Neurological Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00919555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00919555 about?
NCT00919555 is a clinical study titled "Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)". The purpose of the study is to determine the safety and the efficacy of Tretinoin and Pioglitazone HCL in patients with ALS who are currently on Riluzole.
What is the current status of trial NCT00919555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00919555?
The interventions under investigation include: Placebo (DRUG), Pioglitazone and Tretinoin (DRUG), Tretinoin and Pioglitazone HCL (DRUG).
Who is sponsoring clinical trial NCT00919555?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.